Chemicals
Showing 35701–35850 of 41137 results
-
Protein arginine N-methyltransferase 3 (PRMT3, Item No. 11642) is a predominantly cytoplasmic enzyme that is constitutively expressed.{21260,20245} SGC707 is a potent allosteric inhibitor of PRMT3 (IC50 = 50 nM) with >100-fold selectivity over other methyltransferases and other non-epigenetic targets. Developed by the Structural Genomics Consortium (SGC), SGC707 avidly binds PRMT3 (Kd = 50 nM by isothermal titration calorimetry) and inhibits the methylation of histones in cells with an IC50 value below 1 µM.
Brand:CaymanSKU:-Out of stock
Protein arginine N-methyltransferase 3 (PRMT3, Item No. 11642) is a predominantly cytoplasmic enzyme that is constitutively expressed.{21260,20245} SGC707 is a potent allosteric inhibitor of PRMT3 (IC50 = 50 nM) with >100-fold selectivity over other methyltransferases and other non-epigenetic targets. Developed by the Structural Genomics Consortium (SGC), SGC707 avidly binds PRMT3 (Kd = 50 nM by isothermal titration calorimetry) and inhibits the methylation of histones in cells with an IC50 value below 1 µM.
Brand:CaymanSKU:-Out of stock
Protein arginine N-methyltransferase 3 (PRMT3, Item No. 11642) is a predominantly cytoplasmic enzyme that is constitutively expressed.{21260,20245} SGC707 is a potent allosteric inhibitor of PRMT3 (IC50 = 50 nM) with >100-fold selectivity over other methyltransferases and other non-epigenetic targets. Developed by the Structural Genomics Consortium (SGC), SGC707 avidly binds PRMT3 (Kd = 50 nM by isothermal titration calorimetry) and inhibits the methylation of histones in cells with an IC50 value below 1 µM.
Brand:CaymanSKU:-Out of stock
SGI-1027 is an inhibitor of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B (IC50s = 12.5, 8, and 7.5 μM, respectively, with Poly(dI-dC) as the substrate).{20127} It has been shown to cause the degradation of DNMT1 and to reactivate silenced tumor suppressor genes by reducing CpG island hypermethylation.{20127}
Brand:CaymanSKU:11165 - 1 mgAvailable on backorder
SGI-1027 is an inhibitor of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B (IC50s = 12.5, 8, and 7.5 μM, respectively, with Poly(dI-dC) as the substrate).{20127} It has been shown to cause the degradation of DNMT1 and to reactivate silenced tumor suppressor genes by reducing CpG island hypermethylation.{20127}
Brand:CaymanSKU:11165 - 10 mgAvailable on backorder
SGI-1027 is an inhibitor of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B (IC50s = 12.5, 8, and 7.5 μM, respectively, with Poly(dI-dC) as the substrate).{20127} It has been shown to cause the degradation of DNMT1 and to reactivate silenced tumor suppressor genes by reducing CpG island hypermethylation.{20127}
Brand:CaymanSKU:11165 - 5 mgAvailable on backorder
SGI-1027 is an inhibitor of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B (IC50s = 12.5, 8, and 7.5 μM, respectively, with Poly(dI-dC) as the substrate).{20127} It has been shown to cause the degradation of DNMT1 and to reactivate silenced tumor suppressor genes by reducing CpG island hypermethylation.{20127}
Brand:CaymanSKU:11165 - 50 mgAvailable on backorder
The Pim family proteins are serine/threonine kinases involved in cancer progression.{20750} SGI-1776 is a potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively).{26823} While it also inhibits FLT3 and haspin (IC50s = 44 and 34 nM, respectively), SGI-1776 has little effect on several other kinases, including cell cycle kinases.{26823} SGI-1776 induces apoptosis in lymphocytes from patients with chronic or acute lymphocytic leukemia but not in those from healthy donors.{26823,26824} At 10 µM, it reduces STAT3 phosphorylation without reducing STAT3 expression in cancer cells, and this correlates with inhibition of cell proliferation.{26826} SGI-1776 also enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant prostate cancer cells to taxanes.{26827,26825}
Brand:CaymanSKU:-Out of stock
The Pim family proteins are serine/threonine kinases involved in cancer progression.{20750} SGI-1776 is a potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively).{26823} While it also inhibits FLT3 and haspin (IC50s = 44 and 34 nM, respectively), SGI-1776 has little effect on several other kinases, including cell cycle kinases.{26823} SGI-1776 induces apoptosis in lymphocytes from patients with chronic or acute lymphocytic leukemia but not in those from healthy donors.{26823,26824} At 10 µM, it reduces STAT3 phosphorylation without reducing STAT3 expression in cancer cells, and this correlates with inhibition of cell proliferation.{26826} SGI-1776 also enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant prostate cancer cells to taxanes.{26827,26825}
Brand:CaymanSKU:-Out of stock
The Pim family proteins are serine/threonine kinases involved in cancer progression.{20750} SGI-1776 is a potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively).{26823} While it also inhibits FLT3 and haspin (IC50s = 44 and 34 nM, respectively), SGI-1776 has little effect on several other kinases, including cell cycle kinases.{26823} SGI-1776 induces apoptosis in lymphocytes from patients with chronic or acute lymphocytic leukemia but not in those from healthy donors.{26823,26824} At 10 µM, it reduces STAT3 phosphorylation without reducing STAT3 expression in cancer cells, and this correlates with inhibition of cell proliferation.{26826} SGI-1776 also enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant prostate cancer cells to taxanes.{26827,26825}
Brand:CaymanSKU:-Out of stock
The Pim family proteins are serine/threonine kinases involved in cancer progression.{20750} SGI-1776 is a potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively).{26823} While it also inhibits FLT3 and haspin (IC50s = 44 and 34 nM, respectively), SGI-1776 has little effect on several other kinases, including cell cycle kinases.{26823} SGI-1776 induces apoptosis in lymphocytes from patients with chronic or acute lymphocytic leukemia but not in those from healthy donors.{26823,26824} At 10 µM, it reduces STAT3 phosphorylation without reducing STAT3 expression in cancer cells, and this correlates with inhibition of cell proliferation.{26826} SGI-1776 also enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant prostate cancer cells to taxanes.{26827,26825}
Brand:CaymanSKU:-Out of stock
SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl.{38140} It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 µM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib (Item No. 10483) on EGFR inhibition.{38139} In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib.
Brand:CaymanSKU:20111 -Available on backorder
SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl.{38140} It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 µM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib (Item No. 10483) on EGFR inhibition.{38139} In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib.
Brand:CaymanSKU:20111 -Available on backorder
SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl.{38140} It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 µM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib (Item No. 10483) on EGFR inhibition.{38139} In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib.
Brand:CaymanSKU:20111 -Available on backorder
SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl.{38140} It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 µM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib (Item No. 10483) on EGFR inhibition.{38139} In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib.
Brand:CaymanSKU:20111 -Available on backorder
SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2 (IC50s = 4.8 and 2.8 nM, respectively).{43799} It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively) and only inhibits AMPK by more than 50% in a panel of 60 additional kinases when used at a concentration of 1 μM.{43800} SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells with an IC50 value of 1.4 μM. It decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719 (Item No. 16986).{43799} SGK1 inhibitor (50 mg/kg) reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719.
Brand:CaymanSKU:25652 - 1 mgAvailable on backorder
SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2 (IC50s = 4.8 and 2.8 nM, respectively).{43799} It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively) and only inhibits AMPK by more than 50% in a panel of 60 additional kinases when used at a concentration of 1 μM.{43800} SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells with an IC50 value of 1.4 μM. It decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719 (Item No. 16986).{43799} SGK1 inhibitor (50 mg/kg) reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719.
Brand:CaymanSKU:25652 - 10 mgAvailable on backorder
SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2 (IC50s = 4.8 and 2.8 nM, respectively).{43799} It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively) and only inhibits AMPK by more than 50% in a panel of 60 additional kinases when used at a concentration of 1 μM.{43800} SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells with an IC50 value of 1.4 μM. It decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719 (Item No. 16986).{43799} SGK1 inhibitor (50 mg/kg) reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719.
Brand:CaymanSKU:25652 - 25 mgAvailable on backorder
SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2 (IC50s = 4.8 and 2.8 nM, respectively).{43799} It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively) and only inhibits AMPK by more than 50% in a panel of 60 additional kinases when used at a concentration of 1 μM.{43800} SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells with an IC50 value of 1.4 μM. It decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719 (Item No. 16986).{43799} SGK1 inhibitor (50 mg/kg) reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719.
Brand:CaymanSKU:25652 - 5 mgAvailable on backorder
The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer.{29341,29344} SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM.{29341} It is over 1,000-fold selective for c-Met over a panel of other kinases.{29341} SGX523 is orally active and dose-dependently inhibits the growth of a variety of tumor xenografts in mice.{29341,29343} The effectiveness of SGX523 is enhanced when combined with other chemotherapeutic compounds, including inhibitors of EGFR.{29344,29345} SGX523 is metabolized, at least in part, by aldehyde oxidase, an enzyme that differs in activity across different species.{29342}
Brand:CaymanSKU:-Available on backorder
The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer.{29341,29344} SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM.{29341} It is over 1,000-fold selective for c-Met over a panel of other kinases.{29341} SGX523 is orally active and dose-dependently inhibits the growth of a variety of tumor xenografts in mice.{29341,29343} The effectiveness of SGX523 is enhanced when combined with other chemotherapeutic compounds, including inhibitors of EGFR.{29344,29345} SGX523 is metabolized, at least in part, by aldehyde oxidase, an enzyme that differs in activity across different species.{29342}
Brand:CaymanSKU:-Available on backorder
The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer.{29341,29344} SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM.{29341} It is over 1,000-fold selective for c-Met over a panel of other kinases.{29341} SGX523 is orally active and dose-dependently inhibits the growth of a variety of tumor xenografts in mice.{29341,29343} The effectiveness of SGX523 is enhanced when combined with other chemotherapeutic compounds, including inhibitors of EGFR.{29344,29345} SGX523 is metabolized, at least in part, by aldehyde oxidase, an enzyme that differs in activity across different species.{29342}
Brand:CaymanSKU:-Available on backorder
The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer.{29341,29344} SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM.{29341} It is over 1,000-fold selective for c-Met over a panel of other kinases.{29341} SGX523 is orally active and dose-dependently inhibits the growth of a variety of tumor xenografts in mice.{29341,29343} The effectiveness of SGX523 is enhanced when combined with other chemotherapeutic compounds, including inhibitors of EGFR.{29344,29345} SGX523 is metabolized, at least in part, by aldehyde oxidase, an enzyme that differs in activity across different species.{29342}
Brand:CaymanSKU:-Available on backorder
SH-4-54 is an inhibitor of signal transducer and activator of transcription 3 (STAT3; IC50 = 4.7 μM for STAT3 homodimer DNA binding activity).{47057} It selectively inhibits STAT3 homodimer over STAT1 and STAT5 homodimer and STAT3:STAT1 heterodimer DNA binding in EGF-stimulated NIH3T3/hEGFR nuclear extracts containing activated STAT1, STAT3, and STAT5 and decreases STAT3 iNOS, Survivin, and Bcl-2 promoter occupancy in MDA-MB-231 cells. SH-4-54 inhibits growth of glioma, breast, and prostate cancer cell lines that express constitutively active STAT3 (IC50s = 1-7.4, 3.8-4.5, and 5.3-5.8 μM, respectively). In vivo, SH-4-54 (3 mg/kg per day) inhibits tumor growth in the U251MG glioma and MDA-MB-231 breast cancer mouse xenograft models.
Brand:CaymanSKU:25982 - 1 mgAvailable on backorder
SH-4-54 is an inhibitor of signal transducer and activator of transcription 3 (STAT3; IC50 = 4.7 μM for STAT3 homodimer DNA binding activity).{47057} It selectively inhibits STAT3 homodimer over STAT1 and STAT5 homodimer and STAT3:STAT1 heterodimer DNA binding in EGF-stimulated NIH3T3/hEGFR nuclear extracts containing activated STAT1, STAT3, and STAT5 and decreases STAT3 iNOS, Survivin, and Bcl-2 promoter occupancy in MDA-MB-231 cells. SH-4-54 inhibits growth of glioma, breast, and prostate cancer cell lines that express constitutively active STAT3 (IC50s = 1-7.4, 3.8-4.5, and 5.3-5.8 μM, respectively). In vivo, SH-4-54 (3 mg/kg per day) inhibits tumor growth in the U251MG glioma and MDA-MB-231 breast cancer mouse xenograft models.
Brand:CaymanSKU:25982 - 10 mgAvailable on backorder
SH-4-54 is an inhibitor of signal transducer and activator of transcription 3 (STAT3; IC50 = 4.7 μM for STAT3 homodimer DNA binding activity).{47057} It selectively inhibits STAT3 homodimer over STAT1 and STAT5 homodimer and STAT3:STAT1 heterodimer DNA binding in EGF-stimulated NIH3T3/hEGFR nuclear extracts containing activated STAT1, STAT3, and STAT5 and decreases STAT3 iNOS, Survivin, and Bcl-2 promoter occupancy in MDA-MB-231 cells. SH-4-54 inhibits growth of glioma, breast, and prostate cancer cell lines that express constitutively active STAT3 (IC50s = 1-7.4, 3.8-4.5, and 5.3-5.8 μM, respectively). In vivo, SH-4-54 (3 mg/kg per day) inhibits tumor growth in the U251MG glioma and MDA-MB-231 breast cancer mouse xenograft models.
Brand:CaymanSKU:25982 - 25 mgAvailable on backorder
SH-4-54 is an inhibitor of signal transducer and activator of transcription 3 (STAT3; IC50 = 4.7 μM for STAT3 homodimer DNA binding activity).{47057} It selectively inhibits STAT3 homodimer over STAT1 and STAT5 homodimer and STAT3:STAT1 heterodimer DNA binding in EGF-stimulated NIH3T3/hEGFR nuclear extracts containing activated STAT1, STAT3, and STAT5 and decreases STAT3 iNOS, Survivin, and Bcl-2 promoter occupancy in MDA-MB-231 cells. SH-4-54 inhibits growth of glioma, breast, and prostate cancer cell lines that express constitutively active STAT3 (IC50s = 1-7.4, 3.8-4.5, and 5.3-5.8 μM, respectively). In vivo, SH-4-54 (3 mg/kg per day) inhibits tumor growth in the U251MG glioma and MDA-MB-231 breast cancer mouse xenograft models.
Brand:CaymanSKU:25982 - 5 mgAvailable on backorder
SHA-68 is an antagonist of the neuropeptide S receptor (NPSR; IC50s = 22 and 23.8 nM for the NPSR Asn107 and NPSR Ile107 isoforms, respectively).{37267} It is selective for NPSR over a panel of 14 G protein-coupled receptors exhibiting no activity at a concentration of 10 μM. SHA-68 (50 mg/kg) reduces NPS-induced horizontal activity and vertical rearing and climbing in mice. SHA-68 also reduces conditioned reinstatement of cocaine seeking in rats.{37268}
Brand:CaymanSKU:21512 -Out of stock
SHA-68 is an antagonist of the neuropeptide S receptor (NPSR; IC50s = 22 and 23.8 nM for the NPSR Asn107 and NPSR Ile107 isoforms, respectively).{37267} It is selective for NPSR over a panel of 14 G protein-coupled receptors exhibiting no activity at a concentration of 10 μM. SHA-68 (50 mg/kg) reduces NPS-induced horizontal activity and vertical rearing and climbing in mice. SHA-68 also reduces conditioned reinstatement of cocaine seeking in rats.{37268}
Brand:CaymanSKU:21512 -Out of stock
SHA-68 is an antagonist of the neuropeptide S receptor (NPSR; IC50s = 22 and 23.8 nM for the NPSR Asn107 and NPSR Ile107 isoforms, respectively).{37267} It is selective for NPSR over a panel of 14 G protein-coupled receptors exhibiting no activity at a concentration of 10 μM. SHA-68 (50 mg/kg) reduces NPS-induced horizontal activity and vertical rearing and climbing in mice. SHA-68 also reduces conditioned reinstatement of cocaine seeking in rats.{37268}
Brand:CaymanSKU:21512 -Out of stock
SHA-68 is an antagonist of the neuropeptide S receptor (NPSR; IC50s = 22 and 23.8 nM for the NPSR Asn107 and NPSR Ile107 isoforms, respectively).{37267} It is selective for NPSR over a panel of 14 G protein-coupled receptors exhibiting no activity at a concentration of 10 μM. SHA-68 (50 mg/kg) reduces NPS-induced horizontal activity and vertical rearing and climbing in mice. SHA-68 also reduces conditioned reinstatement of cocaine seeking in rats.{37268}
Brand:CaymanSKU:21512 -Out of stock
Shikimic acid is a cyclohexenecarboxylic acid originally isolated from I. religiosum.{46308} It is an intermediate in the biosynthesis of aromatic amino acids in plants and microorganisms. Shikimic acid is also a precursor in the synthesis of oseltamivir (Item No. 16070).{46309} It decreases lipid droplet accumulation in HepG2 cells and 3T3-L1 adipocytes when used at a concentration of 80 µM, as well as increases the levels of phosphorylated AMPK and decreases the levels of MID1IP1 in HepG2 and 3T3-L1 adipocytes when used at 40 µM.{46310} Shikimic acid increases differentiation of oligodendrocyte precursor cells in vitro.{46311} It decreases inflammation and demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at doses of 50-200 mg/kg and reduces symptom progression at a dose of 100 mg/kg.{46311} It also induces remyelination in a model of focal demyelination induced by L-α-lysophosphatidylcholine (LPC) in mouse dorsal spinal cord.
Brand:CaymanSKU:26851 - 1 gAvailable on backorder
Shikimic acid is a cyclohexenecarboxylic acid originally isolated from I. religiosum.{46308} It is an intermediate in the biosynthesis of aromatic amino acids in plants and microorganisms. Shikimic acid is also a precursor in the synthesis of oseltamivir (Item No. 16070).{46309} It decreases lipid droplet accumulation in HepG2 cells and 3T3-L1 adipocytes when used at a concentration of 80 µM, as well as increases the levels of phosphorylated AMPK and decreases the levels of MID1IP1 in HepG2 and 3T3-L1 adipocytes when used at 40 µM.{46310} Shikimic acid increases differentiation of oligodendrocyte precursor cells in vitro.{46311} It decreases inflammation and demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at doses of 50-200 mg/kg and reduces symptom progression at a dose of 100 mg/kg.{46311} It also induces remyelination in a model of focal demyelination induced by L-α-lysophosphatidylcholine (LPC) in mouse dorsal spinal cord.
Brand:CaymanSKU:26851 - 250 mgAvailable on backorder
Shikimic acid is a cyclohexenecarboxylic acid originally isolated from I. religiosum.{46308} It is an intermediate in the biosynthesis of aromatic amino acids in plants and microorganisms. Shikimic acid is also a precursor in the synthesis of oseltamivir (Item No. 16070).{46309} It decreases lipid droplet accumulation in HepG2 cells and 3T3-L1 adipocytes when used at a concentration of 80 µM, as well as increases the levels of phosphorylated AMPK and decreases the levels of MID1IP1 in HepG2 and 3T3-L1 adipocytes when used at 40 µM.{46310} Shikimic acid increases differentiation of oligodendrocyte precursor cells in vitro.{46311} It decreases inflammation and demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at doses of 50-200 mg/kg and reduces symptom progression at a dose of 100 mg/kg.{46311} It also induces remyelination in a model of focal demyelination induced by L-α-lysophosphatidylcholine (LPC) in mouse dorsal spinal cord.
Brand:CaymanSKU:26851 - 5 gAvailable on backorder
Shikimic acid is a cyclohexenecarboxylic acid originally isolated from I. religiosum.{46308} It is an intermediate in the biosynthesis of aromatic amino acids in plants and microorganisms. Shikimic acid is also a precursor in the synthesis of oseltamivir (Item No. 16070).{46309} It decreases lipid droplet accumulation in HepG2 cells and 3T3-L1 adipocytes when used at a concentration of 80 µM, as well as increases the levels of phosphorylated AMPK and decreases the levels of MID1IP1 in HepG2 and 3T3-L1 adipocytes when used at 40 µM.{46310} Shikimic acid increases differentiation of oligodendrocyte precursor cells in vitro.{46311} It decreases inflammation and demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at doses of 50-200 mg/kg and reduces symptom progression at a dose of 100 mg/kg.{46311} It also induces remyelination in a model of focal demyelination induced by L-α-lysophosphatidylcholine (LPC) in mouse dorsal spinal cord.
Brand:CaymanSKU:26851 - 500 mgAvailable on backorder
Shikonin is a naturally occurring naphthoquinine isolated from the dried root of L. erythrorhizon, an herb used in traditional Chinese medicine. It increases glucose uptake by adipocytes and myocytes and inhibits the activity of phosphatase and tensin homolog (PTEN; IC50 = 2.7 µM).{23514,23519} It inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2 (IC50 = 0.3 µM).{23515} Shikonin induces cell death consistent with necroptosis in MCF-7 and HEK293 cancer cell lines.{23516} It inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication at nanomolar concentrations.{23517} Shikonin exhibits anti-inflammatory activity, reducing joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis.{23518}
Brand:CaymanSKU:- Shikonin is a naturally occurring naphthoquinine isolated from the dried root of L. erythrorhizon, an herb used in traditional Chinese medicine. It increases glucose uptake by adipocytes and myocytes and inhibits the activity of phosphatase and tensin homolog (PTEN; IC50 = 2.7 µM).{23514,23519} It inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2 (IC50 = 0.3 µM).{23515} Shikonin induces cell death consistent with necroptosis in MCF-7 and HEK293 cancer cell lines.{23516} It inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication at nanomolar concentrations.{23517} Shikonin exhibits anti-inflammatory activity, reducing joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis.{23518}
Brand:CaymanSKU:- Shikonin is a naturally occurring naphthoquinine isolated from the dried root of L. erythrorhizon, an herb used in traditional Chinese medicine. It increases glucose uptake by adipocytes and myocytes and inhibits the activity of phosphatase and tensin homolog (PTEN; IC50 = 2.7 µM).{23514,23519} It inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2 (IC50 = 0.3 µM).{23515} Shikonin induces cell death consistent with necroptosis in MCF-7 and HEK293 cancer cell lines.{23516} It inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication at nanomolar concentrations.{23517} Shikonin exhibits anti-inflammatory activity, reducing joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis.{23518}
Brand:CaymanSKU:- Shikonin is a naturally occurring naphthoquinine isolated from the dried root of L. erythrorhizon, an herb used in traditional Chinese medicine. It increases glucose uptake by adipocytes and myocytes and inhibits the activity of phosphatase and tensin homolog (PTEN; IC50 = 2.7 µM).{23514,23519} It inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2 (IC50 = 0.3 µM).{23515} Shikonin induces cell death consistent with necroptosis in MCF-7 and HEK293 cancer cell lines.{23516} It inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication at nanomolar concentrations.{23517} Shikonin exhibits anti-inflammatory activity, reducing joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis.{23518}
Brand:CaymanSKU:-
SHP099 is an orally bioavailable inhibitor of SHP2, a non-receptor protein tyrosine phosphatase (IC50 = 71 nM).{34164,34163} It stabilizes SHP2 in an auto-inhibited conformation.{34163} SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.{34163}
Brand:CaymanSKU:20000 -Available on backorder
SHP099 is an orally bioavailable inhibitor of SHP2, a non-receptor protein tyrosine phosphatase (IC50 = 71 nM).{34164,34163} It stabilizes SHP2 in an auto-inhibited conformation.{34163} SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.{34163}
Brand:CaymanSKU:20000 -Available on backorder
SHP099 is an orally bioavailable inhibitor of SHP2, a non-receptor protein tyrosine phosphatase (IC50 = 71 nM).{34164,34163} It stabilizes SHP2 in an auto-inhibited conformation.{34163} SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.{34163}
Brand:CaymanSKU:20000 -Available on backorder
SHP099 is an orally bioavailable inhibitor of SHP2, a non-receptor protein tyrosine phosphatase (IC50 = 71 nM).{34164,34163} It stabilizes SHP2 in an auto-inhibited conformation.{34163} SHP099 suppresses signaling through the Ras-ERK pathway and blocks the proliferation of receptor tyrosine kinase-driven human cancer cells in vitro and in vivo.{34163}
Brand:CaymanSKU:20000 -Available on backorder
SHS4121705 is an orally bioavailable mitochondrial uncoupler.{54188} It increases oxygen consumption rate in L6 rat myoblast cells with an EC50 value of 4.3 μM. SHS4121705 (25 mg/kg per day in the diet) reduces hepatic steatosis, liver triglyceride levels, and plasma alanine aminotransferase (ALT) levels in Stelic animal model (STAM) mice, a model of non-alcoholic steatohepatitis (NASH).
Brand:CaymanSKU:31053 - 1 mgAvailable on backorder
SHS4121705 is an orally bioavailable mitochondrial uncoupler.{54188} It increases oxygen consumption rate in L6 rat myoblast cells with an EC50 value of 4.3 μM. SHS4121705 (25 mg/kg per day in the diet) reduces hepatic steatosis, liver triglyceride levels, and plasma alanine aminotransferase (ALT) levels in Stelic animal model (STAM) mice, a model of non-alcoholic steatohepatitis (NASH).
Brand:CaymanSKU:31053 - 10 mgAvailable on backorder
SHS4121705 is an orally bioavailable mitochondrial uncoupler.{54188} It increases oxygen consumption rate in L6 rat myoblast cells with an EC50 value of 4.3 μM. SHS4121705 (25 mg/kg per day in the diet) reduces hepatic steatosis, liver triglyceride levels, and plasma alanine aminotransferase (ALT) levels in Stelic animal model (STAM) mice, a model of non-alcoholic steatohepatitis (NASH).
Brand:CaymanSKU:31053 - 5 mgAvailable on backorder
SHU9119 is an agonist of melanocortin receptor 1 (MC1R) and antagonist of MC4R (IC50s = 1.2 and 2.9 nM, respectively, for displacement of melanocortin).{41427} It induces cAMP formation in HEK293 cells expressing human MC1R (EC50 = 1.11 nM), but inhibits cAMP formation in cells expressing human MC4R.{41427} In rats, SHU9119 (24 nmol, i.c.v. per day for seven days) increases food intake, body weight, fat mass, and lean mass, with concomitant increases in blood glucose, insulin, and leptin levels via disrupted melanocortin signaling.{41426} Similarly, mice treated with SHU9119 (5 nmol/day, i.c.v.) exhibit food intake-independent increases in body weight and fat mass consequent to MC4R inhibition and subsequent brown adipose tissue dysfunction.{41425}
Brand:CaymanSKU:24152 - 1 mgAvailable on backorder
SHU9119 is an agonist of melanocortin receptor 1 (MC1R) and antagonist of MC4R (IC50s = 1.2 and 2.9 nM, respectively, for displacement of melanocortin).{41427} It induces cAMP formation in HEK293 cells expressing human MC1R (EC50 = 1.11 nM), but inhibits cAMP formation in cells expressing human MC4R.{41427} In rats, SHU9119 (24 nmol, i.c.v. per day for seven days) increases food intake, body weight, fat mass, and lean mass, with concomitant increases in blood glucose, insulin, and leptin levels via disrupted melanocortin signaling.{41426} Similarly, mice treated with SHU9119 (5 nmol/day, i.c.v.) exhibit food intake-independent increases in body weight and fat mass consequent to MC4R inhibition and subsequent brown adipose tissue dysfunction.{41425}
Brand:CaymanSKU:24152 - 500 µgAvailable on backorder
Shz-1 is a Shz that activates cardiac differentiation, inducing the expression of early cardiac genes in mouse pluripotent and embryonic stem cells in vitro at low micromolar concentrations.{24724} In addition, Shz-1 drives differentiation of human peripheral blood mononuclear cells, mobilized by granule colony-stimulating factor, toward a cardiac phenotype.{24724} These Shz-1 treated cells enhance myocardial regenerative repair in cryo-injured rat heart.{24724}
Brand:CaymanSKU:- Shz-1 is a Shz that activates cardiac differentiation, inducing the expression of early cardiac genes in mouse pluripotent and embryonic stem cells in vitro at low micromolar concentrations.{24724} In addition, Shz-1 drives differentiation of human peripheral blood mononuclear cells, mobilized by granule colony-stimulating factor, toward a cardiac phenotype.{24724} These Shz-1 treated cells enhance myocardial regenerative repair in cryo-injured rat heart.{24724}
Brand:CaymanSKU:- Shz-1 is a Shz that activates cardiac differentiation, inducing the expression of early cardiac genes in mouse pluripotent and embryonic stem cells in vitro at low micromolar concentrations.{24724} In addition, Shz-1 drives differentiation of human peripheral blood mononuclear cells, mobilized by granule colony-stimulating factor, toward a cardiac phenotype.{24724} These Shz-1 treated cells enhance myocardial regenerative repair in cryo-injured rat heart.{24724}
Brand:CaymanSKU:- Shz-1 is a Shz that activates cardiac differentiation, inducing the expression of early cardiac genes in mouse pluripotent and embryonic stem cells in vitro at low micromolar concentrations.{24724} In addition, Shz-1 drives differentiation of human peripheral blood mononuclear cells, mobilized by granule colony-stimulating factor, toward a cardiac phenotype.{24724} These Shz-1 treated cells enhance myocardial regenerative repair in cryo-injured rat heart.{24724}
Brand:CaymanSKU:-
SI-2 is an inhibitor of steroid receptor coactivator 3 (SRC-3). It has been shown to selectively reduce the transcriptional activities and the protein concentrations of SRC-3 in cells through direct physical interactions with SRC-3.{31177} SI-2 induces death in various breast cancer cells with IC50 values of 3-20 nM without affecting normal cell viability.{31177} At 2 mg/kg, SI-2 can also inhibit primary tumor growth and reduce SRC-3 protein levels in an MDA-MB-468 breast cancer mouse model.{31177}
Brand:CaymanSKU:-Available on backorder
SI-2 is an inhibitor of steroid receptor coactivator 3 (SRC-3). It has been shown to selectively reduce the transcriptional activities and the protein concentrations of SRC-3 in cells through direct physical interactions with SRC-3.{31177} SI-2 induces death in various breast cancer cells with IC50 values of 3-20 nM without affecting normal cell viability.{31177} At 2 mg/kg, SI-2 can also inhibit primary tumor growth and reduce SRC-3 protein levels in an MDA-MB-468 breast cancer mouse model.{31177}
Brand:CaymanSKU:-Available on backorder
SI-2 is an inhibitor of steroid receptor coactivator 3 (SRC-3). It has been shown to selectively reduce the transcriptional activities and the protein concentrations of SRC-3 in cells through direct physical interactions with SRC-3.{31177} SI-2 induces death in various breast cancer cells with IC50 values of 3-20 nM without affecting normal cell viability.{31177} At 2 mg/kg, SI-2 can also inhibit primary tumor growth and reduce SRC-3 protein levels in an MDA-MB-468 breast cancer mouse model.{31177}
Brand:CaymanSKU:-Available on backorder
SI-2 is an inhibitor of steroid receptor coactivator 3 (SRC-3). It has been shown to selectively reduce the transcriptional activities and the protein concentrations of SRC-3 in cells through direct physical interactions with SRC-3.{31177} SI-2 induces death in various breast cancer cells with IC50 values of 3-20 nM without affecting normal cell viability.{31177} At 2 mg/kg, SI-2 can also inhibit primary tumor growth and reduce SRC-3 protein levels in an MDA-MB-468 breast cancer mouse model.{31177}
Brand:CaymanSKU:-Available on backorder
Siamycin I is a tricyclic peptide originally isolated from Streptomyces and has antiviral and antibacterial activities.{47469,47470} It is active against laboratory strains and clinical isolates of HIV-1 (ED50s = 0.05-0.45 and 0.89-5.7 μM, respectively), as well as the CBL-20 strain of HIV-2 (ED50 = 0.45 μM), in vitro.{47469} Siamycin I inhibits HIV-induced fusion of C8166 T cells with HIV-1-infected CEM-SS cells with an ED50 value of 0.08 μM. It is also active against B. subtilis, M. luteus, and S. aureus (MICs = 1.6-6.3 μg/ml).{47470} Siamycin I inhibits autophosphorylation of the E. faecalis quorum sensing kinase FsrC induced by gelatinase biosynthesis-activating pheromone (GBAP).{47471}
Brand:CaymanSKU:27783 - 1 mgAvailable on backorder
Siamycin I is a tricyclic peptide originally isolated from Streptomyces and has antiviral and antibacterial activities.{47469,47470} It is active against laboratory strains and clinical isolates of HIV-1 (ED50s = 0.05-0.45 and 0.89-5.7 μM, respectively), as well as the CBL-20 strain of HIV-2 (ED50 = 0.45 μM), in vitro.{47469} Siamycin I inhibits HIV-induced fusion of C8166 T cells with HIV-1-infected CEM-SS cells with an ED50 value of 0.08 μM. It is also active against B. subtilis, M. luteus, and S. aureus (MICs = 1.6-6.3 μg/ml).{47470} Siamycin I inhibits autophosphorylation of the E. faecalis quorum sensing kinase FsrC induced by gelatinase biosynthesis-activating pheromone (GBAP).{47471}
Brand:CaymanSKU:27783 - 500 µgAvailable on backorder
SIB 1553A is an agonist of nicotinic acetylcholine receptors (nAChRs) that displays selectivity for β4 subunit-containing receptors.{33653} Formulations containing SIB 1553A improve attentional function and performance in spatial and non-spatial working memory tasks in animals.{33653,33654,33655}
Brand:CaymanSKU:- SIB 1553A is an agonist of nicotinic acetylcholine receptors (nAChRs) that displays selectivity for β4 subunit-containing receptors.{33653} Formulations containing SIB 1553A improve attentional function and performance in spatial and non-spatial working memory tasks in animals.{33653,33654,33655}
Brand:CaymanSKU:- SIB 1553A is an agonist of nicotinic acetylcholine receptors (nAChRs) that displays selectivity for β4 subunit-containing receptors.{33653} Formulations containing SIB 1553A improve attentional function and performance in spatial and non-spatial working memory tasks in animals.{33653,33654,33655}
Brand:CaymanSKU:- SIB 1553A is an agonist of nicotinic acetylcholine receptors (nAChRs) that displays selectivity for β4 subunit-containing receptors.{33653} Formulations containing SIB 1553A improve attentional function and performance in spatial and non-spatial working memory tasks in animals.{33653,33654,33655}
Brand:CaymanSKU:-
Siccanin is an inhibitor of mitochondrial complex II (succinate dehydrogenase; IC50s = 0.87 and 9.3 μM for P. aeruginosa and rat mitochondria, respectively).{41290} It inhibits the growth of T. mentagrophytes (IC50 = 0.3 μg/ml) via inhibition of succinate oxidation in the mitochondria.{41291} It also inhibits the growth of C. albicans strains with IC50 values ranging from 5-40 and 80-90 μg/ml for aerobic and anaerobic conditions, respectively.{41292}
Brand:CaymanSKU:23654 - 1 mgAvailable on backorder
Siccanin is an inhibitor of mitochondrial complex II (succinate dehydrogenase; IC50s = 0.87 and 9.3 μM for P. aeruginosa and rat mitochondria, respectively).{41290} It inhibits the growth of T. mentagrophytes (IC50 = 0.3 μg/ml) via inhibition of succinate oxidation in the mitochondria.{41291} It also inhibits the growth of C. albicans strains with IC50 values ranging from 5-40 and 80-90 μg/ml for aerobic and anaerobic conditions, respectively.{41292}
Brand:CaymanSKU:23654 - 500 µgAvailable on backorder
SID 3712249 inhibits the biogenesis of microRNA-544 (miR-544), a silencer of mammalian target of rapamycin (mTOR).{54014} Under hypoxic conditions, SID 3712249 (20 nM) increases MTOR mRNA expression and decreases the mRNA expression of the genes encoding miR-544, hypoxia-inducible factor-1α (HIF-1α), and ataxia-telangiectasia mutated kinase (ATM) in MDA-MB-231, MCF-7, and MCF-10A cells. It induces apoptosis in MDA-MB-231 cells in a hypoxia- and mTOR-dependent manner when used at a concentration of 20 nM. SID 3712249 (20 nM) enhances the sensitivity of MCF-7 and MDA-MB-231 cells cultured under hypoxic conditions to decreases in cell viability induced by 5-fluorouracil (5-FU; Item No. 14416). It reduces tumor growth in an MDA-MB-231 mouse xenograft model.
Brand:CaymanSKU:29723 - 10 mgAvailable on backorder
SID 3712249 inhibits the biogenesis of microRNA-544 (miR-544), a silencer of mammalian target of rapamycin (mTOR).{54014} Under hypoxic conditions, SID 3712249 (20 nM) increases MTOR mRNA expression and decreases the mRNA expression of the genes encoding miR-544, hypoxia-inducible factor-1α (HIF-1α), and ataxia-telangiectasia mutated kinase (ATM) in MDA-MB-231, MCF-7, and MCF-10A cells. It induces apoptosis in MDA-MB-231 cells in a hypoxia- and mTOR-dependent manner when used at a concentration of 20 nM. SID 3712249 (20 nM) enhances the sensitivity of MCF-7 and MDA-MB-231 cells cultured under hypoxic conditions to decreases in cell viability induced by 5-fluorouracil (5-FU; Item No. 14416). It reduces tumor growth in an MDA-MB-231 mouse xenograft model.
Brand:CaymanSKU:29723 - 25 mgAvailable on backorder
SID 3712249 inhibits the biogenesis of microRNA-544 (miR-544), a silencer of mammalian target of rapamycin (mTOR).{54014} Under hypoxic conditions, SID 3712249 (20 nM) increases MTOR mRNA expression and decreases the mRNA expression of the genes encoding miR-544, hypoxia-inducible factor-1α (HIF-1α), and ataxia-telangiectasia mutated kinase (ATM) in MDA-MB-231, MCF-7, and MCF-10A cells. It induces apoptosis in MDA-MB-231 cells in a hypoxia- and mTOR-dependent manner when used at a concentration of 20 nM. SID 3712249 (20 nM) enhances the sensitivity of MCF-7 and MDA-MB-231 cells cultured under hypoxic conditions to decreases in cell viability induced by 5-fluorouracil (5-FU; Item No. 14416). It reduces tumor growth in an MDA-MB-231 mouse xenograft model.
Brand:CaymanSKU:29723 - 5 mgAvailable on backorder
SID 3712249 inhibits the biogenesis of microRNA-544 (miR-544), a silencer of mammalian target of rapamycin (mTOR).{54014} Under hypoxic conditions, SID 3712249 (20 nM) increases MTOR mRNA expression and decreases the mRNA expression of the genes encoding miR-544, hypoxia-inducible factor-1α (HIF-1α), and ataxia-telangiectasia mutated kinase (ATM) in MDA-MB-231, MCF-7, and MCF-10A cells. It induces apoptosis in MDA-MB-231 cells in a hypoxia- and mTOR-dependent manner when used at a concentration of 20 nM. SID 3712249 (20 nM) enhances the sensitivity of MCF-7 and MDA-MB-231 cells cultured under hypoxic conditions to decreases in cell viability induced by 5-fluorouracil (5-FU; Item No. 14416). It reduces tumor growth in an MDA-MB-231 mouse xenograft model.
Brand:CaymanSKU:29723 - 50 mgAvailable on backorder
Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:10008671 - 10 mgAvailable on backorder
Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:10008671 - 25 mgAvailable on backorder
Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:10008671 - 50 mgAvailable on backorder
Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:- Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:- Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (ANG1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:-
Sildenafil-d3 is intended for use as an internal standard for the quantification of sildenafil (Item Nos. 10008671 | 14008) by GC- or LC-MS. Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (Ang1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:-Available on backorder
Sildenafil-d3 is intended for use as an internal standard for the quantification of sildenafil (Item Nos. 10008671 | 14008) by GC- or LC-MS. Sildenafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with IC50 values of 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum, respectively.{21636} It is selective for PDE5 over PDE1 and PDE3 (IC50s = 0.26 and 65 μM, respectively). Sildenafil reverses glucose-induced decreases in angiopoietin 1 (Ang1) expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro and increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy.{42390} It increases the ratio of maximum intracavernosal pressure to mean arterial blood pressure (ICP/MAP), a measure of erectile function, in castrated rats when administered at a dose of 20 mg/kg per day.{42389} Sildenafil (0.5 mg/kg) also reduces cardiac arrest and resuscitation-induced increases in angiotensin II (Item No. 17150), angiotensin converting enzyme (ACE), ACE2, and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury.{42391} Formulations containing sildenafil have been used in the treatment of erectile dysfunction, pulmonary arterial hypertension, and high-altitude pulmonary edema associated with altitude sickness.
Brand:CaymanSKU:-Available on backorder
Silodosin is a potent α1A-adrenoceptor antagonist (Ki = 0.036 nM).{25007,25008} It shows selectivity for the prostatic adrenoceptor.{25007,25005} As a result, it is effective against lower urinary tract symptoms associated with benign prostatic hyperplasia.{25009,25006}
Brand:CaymanSKU:- Silodosin is a potent α1A-adrenoceptor antagonist (Ki = 0.036 nM).{25007,25008} It shows selectivity for the prostatic adrenoceptor.{25007,25005} As a result, it is effective against lower urinary tract symptoms associated with benign prostatic hyperplasia.{25009,25006}
Brand:CaymanSKU:- Silodosin is a potent α1A-adrenoceptor antagonist (Ki = 0.036 nM).{25007,25008} It shows selectivity for the prostatic adrenoceptor.{25007,25005} As a result, it is effective against lower urinary tract symptoms associated with benign prostatic hyperplasia.{25009,25006}
Brand:CaymanSKU:- Silodosin is a potent α1A-adrenoceptor antagonist (Ki = 0.036 nM).{25007,25008} It shows selectivity for the prostatic adrenoceptor.{25007,25005} As a result, it is effective against lower urinary tract symptoms associated with benign prostatic hyperplasia.{25009,25006}
Brand:CaymanSKU:-
Silodosin glucuronide is an active metabolite of the α1A-adrenergic receptor antagonist silodosin (Item No. 14866).{43909,43910} It is formed from silodosin by the UDP-glucuronosyltransferase (UGT) isoform UGT2B7.{43909} Silodosin glucuronide is toxic to rats with an LD50 value of 0.347 mg/kg.{43910}
Brand:CaymanSKU:28045 - 500 µgAvailable on backorder